@article {896,
	title = {Time to Uveitis Control with Methotrexate and Mycophenolate Mofetil.},
	journal = {Ophthalmology},
	year = {2022},
	month = {2022 Jan 24},
	abstract = {<p>This subanalysis from the First-line Antimetabolites as Steroid-sparing Treatment Trial found no significant difference in the time to achieve a corticosteroid-sparing dosage of prednisone for patients with noninfectious uveitis treated with methotrexate versus mycophenolate mofetil.</p>
},
	issn = {1549-4713},
	doi = {10.1016/j.ophtha.2022.01.020},
	author = {Bui, Anh D and Kong, Christina L and Kelly, Nicole K and Rathinam, S R and Gonzales, John A and Thundikandy, Radhika and Kanakath, Anuradha and Murugan, Bala and Vedhanayaki, R and Lim, Lyndell L and Suhler, Eric B and Al-Dhibi, Hassan A and Doan, Thuy and Acharya, Nisha R}
}
